Metraipolis › archive › dc_434909f6fcdf

Visomitin as a differentiation-inducing therapeutic agent through SYK inhibition in AML — Europe PMC PMID:41815913

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41815913
DOI
10.3389/fphar.2026.1741351
License (as archived)
solo-consultazione
Archived
2026-11-05T08:22:07.329Z
SHA-256 of the archived text
798b41303b189bca1338f92f37e4c18649094c32f85a6aff9cef4bf8ae7a704b
Stable URL of this page
https://metraipolis.com/documento/dc_434909f6fcdf

How to cite

Visomitin as a differentiation-inducing therapeutic agent through SYK inhibition in AML — Europe PMC PMID:41815913 — Europe PMC (en), https://europepmc.org/article/MED/41815913 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_434909f6fcdf (Metraipolis archive dc_434909f6fcdf, sha256 798b41303b189bca1338f92f37e4c18649094c32f85a6aff9cef4bf8ae7a704b)
BibTeX
@misc{dc434909f6fcdf,
  title = {Visomitin as a differentiation-inducing therapeutic agent through SYK inhibition in AML — Europe PMC PMID:41815913},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41815913},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_434909f6fcdf; sha256 798b41303b189bca1338f92f37e4c18649094c32f85a6aff9cef4bf8ae7a704b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41815913. Agents can read the archived copy with the MCP tool read_document.